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REST regulatory circuit controls distinct oncogenic properties of glioblastoma 
stem cells through specific microRNAs 
Anantha Marisetty, M.S. 
Advisory Professor: Sadhan Majumder, Ph.D 
Glioblastoma Multiforme (GBM) is the most common and aggressive primary malignant 
brain tumor in adults. With an average survival of only 12-16 months the prognosis for 
GBM patients remains dismal, with less than 5% of patients surviving 5 years. New 
mechanism-based approaches are necessary for the management of patients with 
GBM. Many GBM tumors are believed to be caused by self-renewing, glioblastoma-
derived stem-like cells (GSCs). These GSCs are resistant to chemo- and radiation 
therapies, and are believed to be responsible for tumor recurrence. In a recent paper 
from our lab we have shown that REST, RE1-silencing transcription factor, regulates 
oncogenic properties such as proliferation, invasion, and apoptosis in GSCs. However, 
the mechanism by which REST regulates oncogenic properties of GSCs is not clearly 
understood. Thus, the overall aim of this project is to delineate the mechanism by 
which REST mediates oncogenic properties of GSCs. Using genome-wide expression 
analysis followed by biochemical validations, we show that REST targets two 
microRNAs, miR-124 and miR-203 in High REST GSCs (HR-GSCs). Independent 
studies were carried out to determine the role of these microRNAs in HR-GSC derived 
brain tumors.  Gain of function of either miR-124 or miR-203 in HR-GSCs leads to 
increased survival when tumor cells are transplanted into mice.  Importantly, the 
increased survival of tumor-bearing mice caused by knockdown of Rest in HR-GSCs 
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can be reversed by double knockdown of Rest and miR-124 or miR-203, indicating that 
the REST-miR-124/miR-203 axis controls tumorigenesis. We further show that the 
REST-miR-124 axis regulates proliferation, invasion and apoptosis of GSCs both in 
vitro and in vivo, while the REST-miR-203 axis specifically regulates invasion and not 
proliferation or apoptosis. Our results indicate that invasion is a major hallmark of HR-
GSC tumors and that the REST-miR-124/203 axis is critical in this process. These 
results also suggest that the REST-miR-124/203 axis could potentially be targeted in 
therapeutic approaches to block invasion in REST-stratified GBM tumors. 
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Chapter 1:  Introduction 
1.1 Overview 
Glioblastoma (GBM; Glioblastoma Multiforme) is the most common and aggressive 
form of adult brain tumors with a mean survival of 12-16 months (1-5). The current 
therapies for GBM patients involve surgical resection followed by radiation and 
chemotherapy or a combination of both (2, 3, 6, 7). Many GBM tumors are believed to 
be caused by self-renewing, glioblastoma-derived stem-like cells (GSCs) that are highly 
proliferative, invasive and resistant to chemo- and radiation therapies, and are believed 
to be responsible for tumor recurrence (8-16). Recent studies from three different 
groups (17-19), including ours, have shown that RE1 silencing transcriptional factor 
(REST) regulates self-renewal and oncogenic properties like proliferation, apoptosis 
and invasion in a class of GSCs. However, the mechanistic understanding of the REST 
driven self-renewal and oncogenesis needs further elucidation. The purpose of this 
study was to determine the mechanism by which REST regulates these oncogenic 
properties (proliferation, apoptosis and invasion) of GSCs and this will produce new 
mechanisms that can potentially be used for novel mechanism-based targeted therapy 
in GBM. 
 
1.2 Glioblastoma (GBM) 
Glioblastoma is one of the most lethal human cancers, accounting 82% of the 
malignant gliomas (16, 20). Gliomas are more common in adults ages 45-65 and affect 
men more than woman (American brain tumor association/ABTA). Based on the 
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histology of the tumor, the World Health Organization (WHO) has classified 
glioblastoma as grade IV tumor of the Central nervous system (20-22). These tumors 
are heterogeneous and characterized by high mitotic activity, microvascular 
proliferation and necrotic areas. Clinical, histological and radiologic evidences suggest 
that the primary GBM arise de novo whereas the secondary GBM arise from the 
progression of pre –existing lower grade gliomas (23).  Primary tumors most commonly 
arise quickly and are very aggressive. These tumors account for the majority of 
glioblastoma and occur in persons age 55 or older. Secondary tumors are usually 
found in persons age 45 or younger, normally start as low grade glioma and ultimately 
transform into malignant rapidly growing gliomas. 
These tumors are highly invasive and the tumor cells invade into the surrounding brain 
parenchyma but do not metastasize (20, 22). As the tumor cells invade the surrounding 
brain, complete surgical resection of the tumor is not possible. The standard care for 
patients who have been newly diagnosed with GBM includes surgical resection 
followed by concurrent adjuvant radiotherapy in combination with the chemotherapeutic 
agent Temozolomide (TMZ, alkylating agent); but still less than 5% of the patients 
survive less than 5 years (24-27).  TMZ have the ability to methylate DNA, leading to DNA 
damage which triggers the death of  tumor cells. However, some cells have an ability to repair 
this type of DNA damage by expressing a protein O6-alkylguanine DNA alkyltransferase (AGT) 
encoded in humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene. In some 
tumors, MGMT is epigenetically silenced preventing the synthesis of this enzyme and thereby 
making the tumors more sensitive to TMZ. A recent study has suggested that methylation 
of the promoter of O6-methguanine-DNA methyl transferase (MGMT) has a survival 
advantage upon chemotherapy with TMZ when compared to the unmethylated 
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promoter status of MGMT (27). This study has established that MGMT promoter 
methylation can be used as a strong predictive marker. There are currently three 
molecular markers that are being used routinely in the clinic which include mutations in 
the isocitrate dehydrogenase 1 and 2 (IDH1/2), codeletion of 1p and 19q chromosomes 
and MGMT promoter methylation (10, 28, 29). These markers have diagnostic, 
prognostic and predictive value and have gained significant clinical relevance. A better 
understanding of the cellular origin and the molecular pathways that regulate these 
tumors needs to be elucidated. 
The recurrence of the disease is mainly due to invasive cells that are radio and chemo-
resistant, especially the cancer stem cells (CSCs). Studies have shown that 
heterogeneous tumors are composed of tumor cells and  a small percentage  of cancer 
stem cells. Cancer stem cells constitute around 2%-3% of the tumor mass. The CSCs 
are highly tumorigenic and have self-renewal potential (30). CSCs are phenotypically 
similar to the normal stem cells, expressing the genes that are the characteristic 
features of neural stem cells and express CD133 gene. The CD133 + cells have a 
higher DNA repair capacity when compared to normal cells as the gene down regulates 
autophagy genes (31, 32).  Studies have also shown that as few as 100 CD133+ cells 
when implanted into the brain of immunodeficient (SCID) mice can reproduce tumors 
but a million CD133- cells cannot reproduce the same tumor (33). Usually CSCs are in 
the quiescent state, but upon surgery, radiation or chemotherapy, they are stimulated 
and proliferate exponentially and are responsible for tumor recurrence. 
In an effort to better understand the genomic changes that occur in glioblastoma, the 
cancer genome atlas research network (TCGA) compiled molecular profiles on GBM 
patient samples and found that when looking at gene expression and mutation data, 
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that GBM could be classified into four subclasses: proneural, neural, classical and 
mesenchymal (8, 21, 34, 35). The proneural subclass is characterized by the 
amplification of platelet derived growth factor receptor -α (PDGFRα) and also 
expresses several proneural development genes, the neural subclass is characterized 
by the presence of neural markers, classical group by the amplification of Epidermal 
growth factor receptor (EGFR) and cdkn2a deletion, and mesenchymal group by the 
loss of neurofibromin (NF1)(8, 21, 34, 36, 37). This classification has helped to 
understand the molecular signature of GBM but did not provide any prognostic tool or 
survival advantage. 
 
Figure 1: Molecular subtypes of GBM.  In an effort to better understand the genomic 
changes that occur in glioblastoma, TCGA did molecular profiles on GBM patient 
samples. Based on the gene expression and mutation data GBM could be classified 
into four subclasses. The four subtypes are Proneural, Neural, Classical and 
Mesenchymal. Figure is taken from reference (38), with the following license number 
3626010907812.  
 
15 
 
1.3 REST 
The Repressor Element-1 (RE-1) silencing transcriptional factor (REST), also 
known as neuron restrictive silencing factor (NRSF), is a major transcriptional 
repressor of neurogenesis in neural cells and neuronal differentiation in non-neural 
cells (39). REST is expressed at higher levels in neural stem cells (NSC) and 
embryonic stem (ES) cells and thereby prevents them from neuronal differentiation 
(40, 41). In mature neurons, REST is expressed at very low levels. REST 
expression is preserved in NSCs and ESCs to ensure these cells maintain stem cell 
properties (39, 42, 43).  Studies have shown that REST is important for normal 
brain development, and homozygous deletion of REST resulted in embryonic 
lethality at E11.5 (44). Most of the studies to date have shown the role of REST in 
embryonic development and neurogenesis. In addition, dysfunction and abnormal 
expression of REST has been found in Downs syndrome, Huntington’s disease and 
medulloblastoma(42). 
REST is a 116 kilo Dalton (kDa)  kruppel type zinc finger transcriptional factor that 
contains a central DNA binding domain (Zn-DBD) consisting of eight zinc finger 
motifs, that binds to the consensus RE1 (or NRSE) sequence on the target genes 
regulatory regions(43, 45, 46). It contains two distinct repressor domains (RD): one 
at the N-terminus (RD1), and the other within the zinc finger motif at the C-terminus 
(RD2)(43, 45).  The central DNA binding domain can recognize two types of RE-1 
motifs on the target genes; a) canonical RE-1 motif and b) non-canonical RE-1 motif 
(47, 48). The canonical and the non-canonical motif differ in the length of the 
insertion between two conserved sequences. The former is characterized by the 
presence of a single nucleotide that separates the conserved sequences while the 
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later has variable length of non-conserved nucleotides. The canonical motif has a 
higher binding affinity to REST suggesting tissue specific functions.  The repressor 
domain RD1 interacts with mSin3A while RD2 interacts with Co-REST (43, 49). 
Both RD1 and RD2 repressor domains recruit the histone deacetylase (HDACs) 
silencing complex to remodel chromatin and represses its target gene expression 
(43, 49) . A recent study using a combination of in silico and biochemical 
approaches has identified 1,892 human, 1,894 mouse, and 554 Fugu RE-1 sites on 
target genes (47). 
 
 
 
Figure 2:  Structure of REST protein. REST contains a DNA binding domain 
(DBD) with eight zinc finger domains and two repressor domains (RD1 and RD2). 
REST recognizes RE1 consensus sequence on the target gene regulatory 
elements. (Adapted from (39, 45) ) 
 
             REST is regulated by ubiquitin mediated proteosomal degradation, β-
Transducin repeat containing protein (β-TRCP) an E3 ligase, promotes REST 
degradation during the G2 phase of cell cycle in ES cells and non-neural cells(50, 
51). Failure to degrade REST attenuates the neuronal differentiation process in 
neural cells. Studies have also identified the ability of USP7 (herpes virus- 
associated ubiquitin specific protease) to compensate REST ubiquitination which 
prevent differentiation through deubiquitination. Deubiquitination mediated by USP7 
and the ubiquitination by β-TRCP together regulate the REST protein levels and its 
function(52). 
 
        
RD1 
11 
DBD RD 2 
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            Depending on the cellular context, REST can function either as a tumor   
suppressor or oncogene. REST is expressed in non-neural tissues such as lung, 
breast and colon epithelium and there by represses neurogenesis (53-56). Inhibition of 
REST in epithelial cells has increased the capability for transformation.  A mutant form   
of REST, which lacks the c-terminus acts as a dominant negative isoform, when 
transfected into colon cells promotes anchorage - independent growth. Most of the 
non-small cell lung cancers (non- SCLC) have normal expression levels of REST at 
protein and RNA level. However, around 10% of the cancers have loss of SWI/SNF 
complex, a cofactor required for REST activity.  Loss of function of REST is also 
observed in other cancers like lung, prostate and breast and successive increase in 
the neuroendocrine genes (53, 54). In non-neural tissues dysfunction or loss of  REST 
leads to neuroendocrine carcinomas suggesting REST contributes to tumor 
development.  In non-neural cancers REST acts as a tumor suppressor by regulating 
cell proliferation and apoptosis. In human mammary epithelial cells (HMECs) knock 
down of REST enhances Akt phosphorylation and inhibition of PI3K signaling and 
there by reduces the transformation capability of the cells (50). Studies have shown 
that in lung and breast cancers loss of function of REST enhances cell proliferation 
and survival and up regulation of BCL-2 gene expression(42). Most of the studies to 
date suggested that in non-neural cells or tissues REST has a tumor suppressor 
function and inhibits growth. However a recent study has shown that conditional 
deletion of REST in colon crypts increased the expression of REST-target genes but 
no significant effect on tumor development is observed(57). 
                   As REST plays an important role in maintenance of NSCs, functional 
abnormality of REST is found in the development of many brain tumors. Interestingly, 
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elevated levels of REST protein have been observed in neuroblastoma and 
medulloblastoma tissues when compared to the surrounding normal tissue. The higher 
expression levels of REST in medulloblastoma and neuroblastoma correlate with poor 
patient survival (42, 56, 58). REST mainly acts as a oncogenic promoter in brain 
tumors.  Studies have shown that ectopic expression of mutant REST, REST-VP16 in 
medulloblastoma cells have significantly reduced the tumorigenic potential of these 
cells (59).  Inhibition of REST in medulloblastoma leads to apoptosis.  A recent study 
has shown that REST regulates hedgehog signaling during embryonic development. 
Hedgehog signaling regulates the proliferation and differentiation of neural stem cells.  
Also, during medulloblastoma development there is an up regulation in the hedgehog 
signaling. Studies have also shown that Wnt signaling pathway that controls properties 
of neural stem cells also regulate the expression of REST. Thus a cross talk between 
these 3 signaling cascades plays an important role in medulloblastoma tumorigenesis. 
REST has very tissue specific function. Inhibition of REST in epithelial cells leads to 
increased proliferation while in medulloblastoma cells leads to increased apoptosis 
(59-61). Studies have shown that REST requires additional partners or oncogenes to 
promote tumorigenesis of medulloblastoma. Over expression of REST alone doesn’t 
promote medulloblastoma tumor formation. Rather co-expression of c-myc is required 
to promote the formation of medulloblastoma tumors (62). Studies have clearly show 
that REST has opposing functions in different tissues; it acts as a tumor suppressor in 
epithelial cells and as an oncogene in brain tumors. The tissue specific roles of REST 
might be attributed to forming different repressor complexes with its co activators. As 
REST plays a crucial role in maintenance of neural stem cells and also development 
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of brain tumors, it is critical to develop a novel therapeutic approach specifically 
targeting REST in cancer cells. 
 
 
1.4 MicroRNAs 
MicroRNAs are small molecules of 20-22 nucleotides endogenous noncoding 
functional RNAs (63-65). They regulate gene expression either by regulating mRNA 
translation or degradation of specific mRNAs that control cellular processes. 
Computation and experimental approaches have discovered that a single microRNA 
can target more than 100 genes mRNA. Studies have shown that 60% of the 
human protein coding genes are predicted to contain miRNA binding sites in their 
3`- untranslated region (UTR ) (64). MicroRNAs activity is primarily through binding 
to the 3`UTR of messenger RNAs resulting in degradation and translational 
repression. microRNAs do not require perfect base pairing unlike other small RNAs 
but can regulate anetwork of specific genes. However studies have also reported 
binding and activity through the 5`-UTR .(66) 
                      A high-throughput screen and functional studies in cancer has 
revealed that miRNAs play important roles in human disease. A small change in the 
expression levels of microRNA has significant effect on the mRNA targets. 
MicroRNAs were found to affect cellular proliferation, apoptosis, invasion, 
angiogenesis, and stemness of the malignant cells. MicroRNAs can be either tumor 
suppressors or oncogenes based on their expression in malignant tissue compared 
to the surrounding normal tissue. 
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                   Accumulating evidences has shown that miRNA expression can be 
used as a prognostic or diagnostic marker in cancers. It has been shown that 
classification of cancers based on their  miRNA expression signature is more 
accurate than their mRNA based signature (29, 67).  It is easy to modulate the 
expression of microRNAs either using antisense oligonucleotides or precursor or 
mimic sequences. The expression profiles of microRNAs differ between the normal 
tissue and tumor tissue and between tumor types.  Studies have shown that 
aberrant microRNA expression can affect cell proliferation, apoptosis, invasion and 
epithelial to mesenchymal transition(63). Additionally, studies have identified 
correlations between microRNA expression and recurrence and survival. 
                       Genome wide analysis and high throughput screenings have 
revealed that some MiRs have RE1 binding sites. Studies have also shown that 
miR-21 is expressed at higher levels in glioblastoma and has survival significance 
(68). Studies have shown that REST regulates the expression of miRs that promote 
neuronal differentiation including miR-124a, miR-9 and miR-132 (42).                               
                   Based on binding studies and expression analyses, miR-124a was one 
of the earliest identified miRs  demonstrated to be a direct target of REST. Studies 
have shown that in NSCs and non-neural cells REST represses miR-124a 
expression, thereby preventing neurogenesis and expression of neuronal genes. 
Two independent studies have shown that treatment of GBM stem cells with miR-
124 led to differentiation of these cells and decreased expression of stem cell 
maintenance proteins(69). This result suggests us that low expression level of miR-
124 in the GBM patient’s results in decreased differentiation and increased 
proliferation of GBM stem cells. 
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                     miR-124 is one of the abundant microRNAs in the brain and is often 
down regulated in GBM patients. Studies have shown that addition of miR-124 in 
the cells that lack them reduces the migratory and invasive potential (69, 70). 
                     MicroRNA, miR-203   has been identified as a tumor suppressor 
microRNA in basal cell carcinomas and hepatocellular carcinoma (71-74). Studies 
have shown that miR-203 is epigenetically silenced in hepatocellular carcinoma 
tumors and leukemias (72, 75). Studies have also shown that it is over expressed in 
pancreatic adenocarcinoma and shows correlation with poor prognosis (76). MiR-
203 has been shown to be up regulated upon UV radiation indicating its role in 
apoptosis (77). Studies have shown that role of microRNAs in malignancy is due to 
translocation of chromosomes or allelic deletions. Recent evidences have shown 
that the 14q chromosome harbors a multiple tumor suppressor genes and plays an 
important role in GBM pathogenesis. This region harbors several microRNAs 
including miR-203. Two independent studies have shown that there is a  allelic 
deletion on chromosome 14q  in 20%-40% patients (78, 79). 
 
1.5 Glioblastoma Stem cells (GSCs) 
 
The recent beginning of the “cancer stem cell” hypothesis has brought a new 
perspective to our understanding of GBM biology and therapy (11, 14). According to 
this hypothesis, GBM tumors contain stem-cell-like cells, known as glioblastoma 
stem cells (GSCs), which have the capacity for long-term self–renewal. GSCs are 
more efficient at forming tumors than non-stem cells and are highly resistant to 
chemo and radiation therapies and are believed to be responsible for tumor 
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recurrence. Several studies have demonstrated that GSCs promote tumor 
angiogenesis and invasion. 
        The glioblastoma stem cells (GSCs) used in the current study are derived from 
the patient tumors that are treated at MD Anderson Cancer Center, for GBM after 
getting patients consent. The tumors are washed and subjected to enzymatic 
dissociation and allowed to recover in a medium that promote only stem cell growth. 
 Our research suggests that REST is expressed at varying levels in these GSCs 
established from patient tumors and helps in maintaining their self-renewal and 
oncogenic properties like proliferation, apoptosis and invasion (17).  This shows the 
heterogeneity of these established cell lines. These GSCs can recapitulate the 
human tumor when implanted into the mice brains. 
              Based on the REST protein expression levels our lab has classified the GSCs     
available as High REST (HR-GSC) and Low REST (LR-GSC) GSCs. We observed that 
GSCs with higher REST expression had a higher self-renewal capacity, sphere forming 
capacity and oncogenic properties when compared to GSCs with lower REST 
expression. Studies have suggested targeting REST for proteosomal degradation may 
disrupt the oncogenic potential of GSCs. 
In order to study the role of REST in self-renewal and GBM tumorigenesis we knocked 
down REST in the HR-GSCs and performed self-renewal and tumorigenic assays. Our 
group and two other groups have observed that upon knocking down of REST there is 
a decrease in the self-renewal capacity, decreased proliferation, increased apoptosis 
and decreased invasion both in vitro and in vivo.  When REST knock down GSCs were 
implanted into the brains of nude mice there is an increased survival of the mice when 
compared to the controls. The tumors formed by HR-GSCs are highly invasive but 
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upon REST knock down the tumors are more circumscribed. Our studies along with 
two other groups indicated that REST is involved in glioblastoma tumorigenesis (17-
19). However, the mechanisms by which REST regulates these tumorigenic properties 
of GSCs are still unclear.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: REST regulates oncogenic properties of Glioblastoma Stem cells 
(GSCs). When REST is expressed at higher levels there is an increase in level of 
proliferation and invasion and decreased apoptosis leading to increased tumorigenesis 
both in vitro and in vivo. When REST is expressed at lower levels there is decreased 
proliferation and invasion and increased apoptosis leading to decreased tumorigenesis 
both in vitro and in vivo. 
 
 
 
Apoptosis Invasion 
Tumorigenesis  
 
 
      Proliferation  Apoptosis 
REST  
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Chapter 2:  Material and Methods 
2.1. Cell culture 
GSCs used for this study were  obtained from the Brain Tumor center core, and  were 
established from human GBM surgical specimens from patients treated at 
The University of Texas MD Anderson Cancer Center, Houston, TX as described 
previously (17). The cells are maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) F12 (Sigma) supplemented with B-27 (1:50, Gibco), L-glutamine (1:100, 
sigma), 20 ng/ml epidermal growth factor (Sigma), 20 ng/ml fibroblast growth factor, 
and Penstrep (1:100) as previously described (17). Cells were maintained at 37°C with 
5% CO2. These cells were grown as spheres, fed every 2 days, and split in half once 
the sphere size reached 100 µm with Accutase (Sigma) and seeded as single cells. 
The cells are frozen as single cells in 10% FBS, 20% DMSO and 70% basal medium 
with no growth factors.  
2.2. siRNA transfections 
All siRNA transfections were performed using Amaxa nucleofector technology (Lonza) 
.Four million cells were suspended in 90µl of amaxa buffer. 10µl of siRNA at a 
concentration of 20µg/µl is added to the amaxa buffer to make a final volume of 100µl. 
The samples are subjected for electroporation and immediately resuspended in 500µl 
fresh medium. siNT (control/non targeting )and siRest siRNAs are obtained from 
dharmacon (GE Health care). 
 
 
25 
 
2.3. Total RNA isolation 
Total RNA was extracted from the GSCs using Trizol reagent (Invitrogen, Carlsbad, 
CA) according to manufacturer’s instructions. Briefly the cell pellets are lysed using 1ml 
of Trizol reagent followed by chloroform extraction by centrifugation at 13,000rpm for 
15 min at 4° C. The aqueous phase was collected and precipitated with equal volumes 
of isopropanol. Glycogen is added at 1mg/1ml at this step as it aids in precipitation. The 
samples were further centrifuged at 13,500 rpm for 15min at 4°C. The pellet  were 
washed with 1ml of 70% RNAse free ethanol and centrifuged at 7500rpm for 5min at 
4°C. The pellets are air dried and resuspended in RNAse free water. Concentration of 
RNA was determined by spectrophotometric analysis using Nanodrop (Thermo 
scientific, Rockford, IL). The samples are stored at -80°C for future use. 
2.4. Genome-wide expression analysis of GSCs with loss-of-function of REST 
(Microarray) 
Total RNA was extracted from the transient transfections of siRest and siNT cells.  
RNA purity was assessed using Nanodrop spectrophotometric measurement of optical 
density (OD) 260/280 ratio of greater than 1.85. miR microarray was performed 
(Affymetrix, U-133 plus 2.0 array) by  labelling and hybridizing using five hundred 
nanograms of the total RNA according to manufacturer’s protocol. Bioinformatic 
analysis was performed by using R (2.14.2) program to identify the miRs with a two fold 
increase upon REST knockdown with a significant p value (p<0.05) 
2.5. Western blotting 
Whole cell extracts were prepared  by using lysis buffer ((150mM NaCl, 25mM Tris, pH 
7.5,5mM EDTa,1% Triton X,0.1% SDS,0.5% sodium deoxycholate)  with 1X protease 
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inhibitors. Briefly, after the addition of lysis buffer the samples were kept on ice for 30 
minutes with frequent vortexing every 5 minutes. The samples were centrifuged at 
13,000rpm for 15 minutes. The supernatant was collected and quantified using a BCA 
protein assay reagent kit (Pierce Biotechnology, IL).  Samples were resolved by loading 
50 µg of the lysates onto gradient HEPES gels (Pierce Biotechnology, IL). The proteins 
are transferred to a nitrocellulose membrane and blocked with 5% milk followed by 
incubation with rabbit anti-REST antibody (Millipore, USA) overnight at 1:1000 dilution 
or mouse anti-actin (1:10,000) and then incubation with fluorescent-labeled secondary 
antibody for 1 hour. The membranes were scanned using the Licor program (Odyssey 
detection system) to visualize the protein complexes. 
2.6. Reverse Transcriptase Polymerase chain Reaction (RT-PCR) 
Complementary DNA (c-DNA) was synthesized by using 1µg of total RNA using the 
verso c-DNA synthesis kit (Thermo Scientific) according to manufacturer’s instructions. 
Briefly, 4µl of 5X cDNA synthesis buffer, 2 µl of 10mMdNTPs, 1ul of primer (1:3 ratio of 
oligo dT and random hexamers), 1µl of RT enhancer and 1µl of verso enzyme and 1µg 
of total RNA diluted in water to make a total volume of 20µl. Reverse transcription was 
done at 42°C for 30min. 
2.7. Quantitative real-time PCR 
The c-DNA synthesized was diluted to bring to a working concentration of 5ng/µl.  
Quantitative PCR (qPCR) was done using SYBR green master mix (Applied 
biosystems,CA) and primers for the 7 microRNAs identified in the screen (miR-124 
,miR-136, miR-203,miR-518e,miR-545,miR-557,miR-942). Primer sequences are 
shown in the Table. Analysis was performed on ABI 7900 real time PCR system 
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(Applied biosciences). Relative miRNA measurements were done using delta Ct 
method as described previously(80). All the experiments were done in triplicates 
List of miR Primers that are potential targets of REST 
Table 1:  Primers for validation of microarray results by qRT-PCR 
Primer Forward Primer Reverse Primer 
miR-124 5`-TCCGTGTTCACAGCGGAC-3’ 5`-CATTCACCGCGTGCCTTA-3’ 
miR-136 5`- 
GGACTCCATTTGTTTTGATGATG-
3’ 
5`- 
AGACTCATTTGAGACGATGATGG-
3’ 
miR-203 5`- 
TCCAGTGGTTCTTAACAGTTCA-3’ 
5`- GGTCTAGTGGTCCTAAACATT-
3’ 
miR-518e 5`- GTTTTCTCAGGCTGTGACC-3’ 5`- GTGTGTTCTCAGGCTGTGAC-3’ 
miR-545 5`- TTGCCCAGCCTGGCACCAT-3’ 5`- GTTTTTCCCAGCTGGCA-3’ 
miR-557 5`- 
GTAGAATGGGCAAATGAACAGT-
3’ 
5`- TTGTTCATGCTAAGAAT-3’ 
miR-942 5`- 
GGATTAGGAGAGTATCTTCTCT-3’ 
5`- TGTGTGATTAGGAGAGTATC-3’ 
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2.8. Taqman assays to measure miR-124 and miR-203 expression 
Total RNA was extracted as described in total RNA isolation section of the methods. 
Mature microRNA expression levels of miR-124 and miR-203 were quantified using 
Taqman®microRNA (Applied Biosystems, CA). Taqman® MicroRNA reverse 
transcription kit (Applied Biosystems, CA) was used to synthesize cDNA using specific 
primers for miR-124, miR-203 and Sno135 according to manufacturer’s protocol. The 
quantitative PCR was performed using Taqman® universal master mix with No Uracil 
N-Glycosylase( UNG) ( Applied Biosystems, CA) on ABI  7900 real time PCR machine 
(Applied biosciences). Relative expression levels of miR-124 and miR-203 were done 
 
2.9. Chromatin Immunoprecipitation (ChIP) Assay 
GSCS dissociated into single cells by accutase were cross-linked at room temperature 
for 10 minutes using 2%formaldehyde. Cross linking was stopped by the addition of 
1/10 volume of 1.4M glycine and rocking for 5 minutes. The cells are washed in 5ml of 
1XPBS by spinning at 1200rpm for 2 minutes. The pellets were rewashed in 10ml of 
fresh PBS with 100µl of protease inhibitor and  sonication wash buffer (10mM HEPES, 
pH 7.5, 200mM NAcl,1mM EDTA,0.5mM EDTA) . The pellets were resuspended in lysis 
buffer (150mM NaCl, 25mM Tris, pH 7.5,5mM EDTA,1% Triton X,0.1% SDS,0.5% 
sodium deoxycholate) and left on ice. The samples were sonicated with a continuous 
pulse at 65 amplitude for 15 seconds for 13 cycles.  A small portion of the sample is 
reverse cross-linked and DNA is recovered and size of the DNA was determined. This 
yielded us a higher concentration of DNA at 500bp with increasing amounts of smaller 
fragments which indicated further sonication is not necessary. The samples were 
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precleared for immunoprecipitation by incubating with protein A beads for 2 hours at 4° 
C. The beads were collected by centrifugation and the supernatant is transferred to a 
new tube. A small aliquot of the sample is saved as an input and the remaining sample 
is divided into 2 equal aliquots for immunoprecipitation using anti-REST, anti-IgG 
antibody. The samples were incubated overnight at 4 °C.   Any residual debris was  
removed by centrifugation. To the supernatant fresh Protein A beads were added and 
incubated for an hour at 4 °C. Beads were recovered by centrifugation and the 
supernatant was  stored at -80C for future use. Beads were further washed in  RIPA 
buffer (50mM Tris pH 8.0,150mM Nacl,0.1% SDS,0.5% sodium deoxycholate ,1% NP-
40,1mM EDTA) for 10 min and the supernatant was recovered by centrifugation. 
Further the beads were washed with 1X high salt solution(50mM Tris pH 8.0,500mM 
Nacl,0.1% SDS,0.5% sodium deoxycholate ,1% NP-40,1mM EDTA) to disrupt protein-
protein interactions. In order to break the RNA fragments the beads are further washed 
with 1X LiCl wash (50mM Tris pH 8.0,250mM Licl,0.1% SDS,0.5% sodium 
deoxycholate ,1% NP-40,1mM EDTA). The beads are washed in TE buffer (10mM Tris 
pH 8.0,1mM EDTA) followed by proteinase K treatment to remove the bound proteins. 
The samples along with the inputs were subjected to reverse crosslinking overnight at 
65°C. The samples were extracted twice using equal volumes of phenol /chloroform.  
The final aqueous phase is collected and the DNA is precipitated using 1/10 volume of 
3M sodium acetate, 2.5 volumes of ethanol and glycogen (carrier molecule) and stored 
at -80C for 2 hrs. DNA is collected by spinning at 13,000 rpm for 20 minutes followed 
by washing with 70% ethanol. The pellets are air dried and resuspended in water and 
stored at -20°C. PCR was performed after a 1:5 dilution of the samples. qRT-PCR was 
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performed and the analysis was done by fold enrichment method as described 
previously. 
2.10. Identification and validation of REST response elements in the promoter 
regions of miR-124/203 
REST binding sites on the promoter region of miR-124 and miR-203 were determined 
using Mat Inspector (Genomatix software suite v3.3), a tool that identifies 
transcriptional factor binding sites. RT-PCR was performed by using primers specific 
for the indicated regions as shown in the following tables 
Table 2: List of primers for potential RE1 binding sites on the gene chromatin of 
miR-124 
Site Forward Primer Reverse Primer 
RE1 site # 1 
-2648bp 
5`- 
CCGCATTTTCCTTGGCACAG-
3’ 
 
5`-ACCAGCACACGTCATTCTCA-3’ 
RE1 site # 2 
(Nonspecific) 
-300bp 
5`- 
GGAAAAAGCCTGGATGCGAA-
3’ 
5`-TCCCCCAATCACACAGACAAT-
3’ 
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Table 3: List of  primers for potential RE1 binding sites on the gene chromatin of 
miR-203 
Site Forward Primer Reverse Primer 
RE1 site # 1 
-223bp 
5’- CGTCTAAGGCGTCCGGTA- 3’ 5’-  
GAGCTGCGGAGAGAGGAG- 
3’ 
RE1site #2 
-512bp 
5’- GCCCAGACGAGACGGTTC- 
3’ 
5’- 
CCGCGACTGATCCTCCAC- 
3’ 
RE1site #3 
-762bp 
5’- CACACCCACCGGAGAGCTA- 
3’ 
5’-
CCCGAACCGTCTCGTCTG-‘3 
RE1 site # 4 
-1223bp 
5’-
CAACCCCATACAGACACACTAA- 
3’ 
5’-
TGTCCAGGCCTGACCAGT-‘3 
RE1site #5  
nonspecific site  
(-2167) 
5’- CCGTCCTCTCTCGTCAGT- 3’ 5’-CTCCCAAAGTGCTGGATT- 
3’ 
 
2.11. Dual Luciferase Assay 
The reporter construct pRLTK along with the PGL3- basic vector or PGL-3 with RE-1 
sites of miR-124  (site #1) or miR-203 (site #4), PGL3 with mutated RE-1 site on miR-
124 or miR-203 were co transfected into High REST and REST knock down cell lines 
by Amaxa electroporation. The DNA fragment containing the REST binding site 
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identified by chip was amplified from genomic DNA of HR-GSC2 line by PCR with 5’ 
XhoI and 3’ HindIII restriction sites. 
Forward Primer 5’-ATACTCGAGGGTGGCTGTGTTCTGGTCTG-3’ and Reverse 
primer 5’- ATAAAGCTTGCTAGCTCTCCGGTGGGT-3’. The mutant version is 
generated using the quick change mutagenesis kit (Agilent technologies). 48 hours 
post transfection luciferase activity was measured with dual –luciferase reporter assay 
(Promega) according to manufacturer’s protocol. 
2.12. Cell Transductions 
Gain of function of miR-124/203: HR-GSC shNT cells have higher expression of 
REST and lower expression levels of miR-124 and miR-203, so we used these cells to 
over express miRs. The cells were transduced with either shNT control or premiR-
124/203 lentiviruses (Thermo scientific Fisher, USA). Transduction efficiency was 
initially checked by fluorescence microscopy, as the vectors have a GFP tag. 
Overexpression of the miRs was further confirmed by qRT-PCR. 
Loss of function of miR-203: HR-GSC shREST cells have lower expression of REST 
and higher expression levels of miRs. Cells were transduced using viruses for control 
shNT or shmiR-203 (Genocopeia, USA). Knockdown was confirmed by qRT-PCR. 
The generated and expression confirmed cell lines for  both miR-124 and miR-203 
overexpression and knockdown were used for assessing the cells tumorigenic 
properties by performing proliferation, invasion, and apoptosis assays in vitro. 
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2.13. In vitro Proliferation assay 
Proliferation assays were performed on the control and miR-altered cell lines using a 
colorimetric BrdU assay kit (Roche, Germany). Briefly, 3000 cells per well were seeded 
8 hours before the BrdU labeling. The cells were incubated with BrdU labeling reagent 
for 24 hours , fixed and DNA is denatured by the addition of fixadent (proprietary 
solution, Roche ,Germany)  which makes the labelled BrdU more accessible to the 
antibody in the next step. The cells are incubated with anti-BrdU antibody for 2 hours. 
The substrate was added and upon color development the color measured at 492 nm. 
The intensity of the color developed is directly proportional to the amount of DNA being 
synthesized and there by number of proliferating cells. All experiments were done in 
triplicates. 
2.14. In vitro cell death detection 
The assays were performed using a cell death detection ELISA PLUS kit (Roche, 
Germany).  The assay is based on the principle of using monoclonal antibodies 
directed against DNA and histones. Briefly the lysates are plated onto streptavidin 
coated plates and incubated with a mixture of anti-histone-biotin and anti-DNA-POD. 
The anti-histone antibody binds to the immunocomplexes and at the same time binds to 
the streptavidin coated on the plate with the cell lysate. The DNA POD antibody reacts 
with the DNA of the nucleosome.  The amount of POD is determined by using ABTS 
substrate. 
2.15. In vitro invasion assay 
Invasion assays (BD biosciences) were performed on the control and miR-altered cell 
lines as described previously (17) . Briefly, 5000 cells were seeded in the upper 
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compartment of the control or invasion chambers. Ten percent fetal bovine serum was 
added to the lower chamber, which acts as a chemo-attractant. Cells were incubated 
for 24 hours at 37°C and 5% CO2. The chambers were fixed with methanol and stained 
with crystal violet. Cells were counted under a microscope and compared to controls. 
All experiments were done in triplicates. 
2.16. Mouse orthotopic GBM models 
All the mouse experiments were carried out according to protocols approved by the 
Institutional Animal Care and Use Committee at The University of Texas MD Anderson 
Cancer Center. Based on the power analysis for each cell type, eight nude mice 4-5 
weeks old (obtained from the Department of Experimental Radiation Oncology at MD 
Anderson Cancer Center) were used. The cells transduced with vector alone were 
used as controls. Brain orthotopic tumor models were generated as described 
previously (17). Briefly, 50,000 cells were implanted in a total volume of 5 µl into the 
right frontal lobes of the mice as shown in figure 3.  Prism 6.01 [Graph pad] was used 
to generate the Kaplan Meir survival curves. 
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Figure 4: Implantable guide screw system for orthotopic brain tumor models. 
Male nude mice of 4-5 weeks old are bolted with either plastic or metallic bolts and 
allowed to recover for 10 days and altered GSCs are injected through the bolt. Tumor 
growth is monitored by MRI imaging and the brain tissue is collected after 45 days. In 
vivo assays are performed on the brain sections. Figure modified from (81) 
 
2.17. In vivo proliferation assay 
The paraffin sections were incubated at 60°C for 30 minutes. This allows the melting of 
paraffin and binding of the tissue to the glass slide.  Following this, the sections were 
hydrated through alcohol grades after clearing with 3 times in xylene. Antigen retrieval 
was performed with citrate buffer in a steamer for 20 minutes and allowed to cool for 1 
hour. Sections were blocked in 5% goat serum for 1 hour followed by incubation with 
human-specific NuMA antibody (1:100; Abcam) overnight at 4°C.  After washing twice 
with 1X phosphate-buffered saline plus 0.1% Tween-20, the sections were incubated 
with Ki67 antibody (1:500, Dako Clone MB-1) for 1 hour and washed twice with 
phosphate-buffered saline followed by incubation with secondary antibodies. The slides 
were mounted with DAPI and double-positive cells (Ki67 and NuMA) were counted 
from 10 different fields with the fluorescent microscope. 
 
10 days  
Altered GSCs are injected  Bolt 
45 days  
Brains are collected  
Paraffin embedded and 
Tumorigenic assays 
4-5 weeks of age  
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2.18. In vivo apoptosis assay 
In vivo TUNEL assay was performed according to the manufacturer’s instructions 
(Roche, Germany). Briefly, after hydrating the paraffin sections through alcohol grades, 
antigen retrieval was performed and the slides were blocked for 1 hour in 3% bovine 
serum albumin and 20% fetal bovine serum. After washing, the slides are incubated 
with TUNEL reaction mixture at 37°C in a humidified atmosphere followed by mounting 
with DAPI. Positive cells were counted in 10 different fields. 
2.19. In Vivo Invasion assay 
Invasion potential of the cells was determined by staining with a NuMa antibody as 
described in the section in vivo proliferation assay.. 
2.20. Statistical analysis 
An unpaired two-tailed Student`s t-test was performed to evaluate the differences 
between the control and treatment groups. All quantified data represent at least three 
independent experiments. 
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Chapter 3:  Aim of the study 
REST promotes oncogenic properties of GSCs both in vitro and in vivo. It affects the 
survival of the tumor bearing mice. Earlier studies have found that REST is 
overexpressed in class of medulloblastoma tumors causing the blockage of neuronal 
differentiation.  Deregulation of normal expression of REST leads to tumor formation. 
The main goal of the project is to delineate the mechanism by which REST regulates 
oncogenic properties in GSCs. REST is predicted to regulate more than 1000 genes, it 
is crucial to identify the major downstream targets of REST that play an important role 
in regulating the oncogenic properties of GSCs.  We considered the microRNA targets 
that are regulated by REST as they are fewer in number (1800) when compared the 
genes (21,000). 
Aim 1: To identify and validate the potential miR-targets of REST that play role in 
GSC tumorigenesis 
microRNA microarray was performed on siRest or siNT (control)  transfected HR-
GSCS. As REST is a transcriptional repressor we considered the microRNAs that are 
up regulated upon REST knock down.  We identified two potential microRNAs, miR-
124 and miR-203 that are regulated by REST. The identified potential REST targets 
were validated by taqman assays and REST binding to the gene chromatin of these 
microRNAs was confirmed by ChIP and luciferase assays. 
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Aim 2:  To determine whether REST - miR-124 axis regulates oncogenic 
properties of GSCs in vitro and in vivo 
miR-124 was identified as one of the potential targets of REST from our screen. miR-
124 is the most abundant microRNA in adult and embryonic brain. Studies have shown 
that REST functions as a negative regulator of miR-124 in NSCs. In this aim we tested 
if miR-124 regulates oncogenic properties of GSCs and does the REST-miR-124 axis 
has any role in GSC tumorigenesis. We performed LOF and GOF of miR-124 by 
lentiviruses in GSC cells and performed in vitro and in vivo tumorigenic assays 
(proliferation, invasion and apoptosis). We observed that over expression of miR-124 
leads to decreased proliferation and invasion and increased invasion both in vitro and 
in vivo. GOF of miR-124 has increased the survival in tumor bearing mice when 
compared to its controls. 
 
Aim 3:  To determine whether REST mediated control of miR-203 regulates 
oncogenic properties of GSCs in vitro and in vivo 
Another novel microRNA target that has been identified in our screen was miR-203. 
This aim tests if REST-miR-203 axis regulates the oncogenic properties of GSCs both 
in vitro and in vivo. LOF and GOF of miR-203 GSCs were made by lentiviral 
transduction. Oncogenic potential of these cells was validated by proliferation, 
apoptosis and invasion assays. We observed either overexpression or knock down of 
miR-203 did not have any role in regulating the cell proliferation or apoptosis of these 
cells both in vitro and in vivo.  But overexpression of miR-203 lead to decreased 
invasion potential of these cells both invitro and in vivo. Also, overexpression of the 
miR-203 in these cells led to increased survival of the tumor bearing mice. 
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Figure 5: Schematic representation of REST regulatory circuit in tumorigenesis.  
REST might be regulating the tumorigenesis of GSCs either through either of the miRs 
or both the miRs. 
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Chapter 4:  Identification and validation of REST-miR targets that may play a role 
in GSC tumorigenesis 
 
Rationale 
As reviewed in the introduction, our group and two other groups have shown that REST 
regulates the oncogenic properties of GSCs (17, 18). When REST is expressed at 
higher levels there is an increase in cell proliferation, invasion, self-renewal and 
decrease in apoptosis both in vitro and in vivo.  GSCs with high REST(HR-GSCs) 
produced more infiltrative tumors while low REST GSCs (LR-GSCs) produced 
circumscribed tumors. A schematic representation of REST regulating oncogenic 
properties is shown in figure 3. REST regulates survival in orthotopic mouse tumor 
models.  However, the mechanistic understanding of the REST driven self-renewal and 
oncogenesis needs further elucidation.  REST is predicted to regulate more than 1000 
genes, it is crucial to identify the major downstream targets of REST that play an 
important role in regulating the oncogenic properties of GSCs . Hence, the identification 
of mechanism(s) by which REST regulates oncogenic properties of GSCs will foster 
development of targeted therapy downstream of REST. 
In this section, we identified the potential microRNA targets of REST that might play a 
role in GSC tumorigenesis by performing a microRNA microarray on REST loss of 
function cells. The identified microRNA targets were first validated by qRT-PCR to 
confirm the microRNA microarray results. Two potential microRNAs, miR-124 and miR-
203 were identified and validated. Taq man assays were performed to find the 
expression levels of mature microRNAs in both loss and gain of function of REST cells.  
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REST binding to the gene chromatin of the miRs was further confirmed by ChiP assay 
and luciferase assay. Together our data suggest that miR-124 and miR-203 are the 
potential microRNA targets of REST and are differentially regulated with REST 
expression. 
 
Results 
REST directly targets miR-124 and  miR-203 and forms the REST-miR-124/ REST-
miR-203 axis 
To determine potential miR targets of REST in GSCs, we performed genome wide 
profiling using microRNA microarray. To represent REST loss of function 
manipulations, we transiently transfected two high-REST (HR)-GSC cell lines (HR-
GSC1 and HR-GSC2), with small interfering RNA Rest, (siRest) or a non-targeting 
control (siNT). A total of four cell lines: HR-GSC1/siNT, HR-GSC1/siRest, HR-
GSC2/siNT, and HR-GSC2/siRest were generated. We used siRNA in these 
experiments to identify the potentially immediate direct targets of REST.  We then 
performed a genome-wide miR expression analysis,  As REST is a repressor 
transcriptional factor we looked into the microRNAs that are up regulated when REST 
is knocked down with a fold change of 2 or more with a  significant p value of p<0.05. 
Whereas 128 miRs in HR-GSC1 and 43 miRs in HR-GSC2 had higher expression in 
the siRest-treated cells than in the siNT controls, only seven miRs were common 
between HR-GSC1 and HR-GSC2 in this differential analysis, as shown in (Fig 6). A 
tabular representation of the 7 microRNAs that are up regulated upon REST knock 
down, their fold changes in each cell line and chromosomal locations is shown in table 
4. 
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Figure 6: Venn diagrammatic representation of the microRNAs that are up 
regulated upon REST knock down in both the cell lines. In HR-GSC 1 and HR-
GSc2 128 and 43 microRNAs are upregulated upon REST knock down. There are 7 
microRNAs that are common in both the lines. 
 
 
Table 4: Tabular representation of microRNAs that are up regulated upon REST 
knock down. Upon REST knock down in both HR-GSCs, 7 microRNAs are 
upregulated with a fold change of 2 or more. 
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We first validated the microRNA microarray data by performing qRT-PCR. We 
observed that microRNAs miR-124 and miR-203 were up regulated in both the HR-
GSCS upon REST knock down with a significant p value (p< 0.05). On the other hand 
the other microRNAs are not up regulated in both the cell lines with a significant p value 
(Fig 7). 
Interestingly, miR-124, a well-known target of REST with a critical function in 
neurogenesis was also identified in our screen. The capture of only a few miRs by this 
analysis suggested that most of the REST miR targets are cell-line dependent and that 
REST function is highly context dependent, as we found earlier. 
 
Figure 7: Validation of microRNA microarray by quantitative real time PCR (qRT-
PCR). Seven microRNAs that are found be upregulated upon REST knock down were 
validated by qRT-PCR. miR-124 and miR-203 expression was significantly upregulated 
upon REST knock down in both the lines when compared to the others. Expression of 
miR-557 and miR-942 was not detected. 
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Two High REST cell lines are transduced with shRest or shNT lentiviruses (HR-
GSC1shNT, HR-GSC1shRest, HR-GSC2 shNT, HR-GSC2shREST). REST expression 
was confirmed by western blotting in loss of function of Rest cells. From the same cells 
total RNA was extracted and the expression of miR-124 and miR-203 was confirmed by 
taq man assays. Both miR-124 and miR-203 were up regulated upon REST knockdown 
in both the GSCs as shown in Fig (8A & 8B) 
 
Figure 8:   miR-124 and miR-203 are upregulated upon REST knock down.  
A. Confirmation of REST knockdown in both the HR-GSC lines by western blotting. B. 
Upregulation of miR-124 and miR-203 is observed upon REST knockdown with a 
significant p value. 
 
To further confirm the results obtained by REST loss-of-function manipulations, we 
performed REST gain-of-function manipulations in two low-REST (LR)-GSC lines by 
introducing either exogenous REST or the green fluorescence protein (GFP) control 
and confirmed the REST overexpression using Western blotting as shown in Figure 9. 
We determined the expression levels of miR-124 and miR-203 in these cells by taq 
A B 
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man assays.  As shown, overexpression of REST consistently suppressed the 
expression of  miR-124 and miR-203 in both the LR-GSC lines ( Fig 9 A & 9B). 
 
 
Figure 9:  miR-124 and miR-203 are suppressed upon REST overexpression.  
A. Immunoblot confirmation of REST expression in REST overexpression LR-
GSCs. B. Taqman assays was performed to measure the relative expression 
levels of both the miRs.  Both the microRNAs miR-124 and miR-203 were 
suppression upon REST overexpression. 
 
To confirm whether miR-124 or miR-203 expression was suppressed by direct binding 
of  REST on the gene chromatin, we performed bioinformatic analysis using 
matInspector (Genomatix software suite) to determine potential REST binding sites 
(RE1s) present on the miR-124 or miR-203 promoter elements 3000bp upstream and 
downstream of the miR-124 or miR-203 start site. We then performed chromatin 
immunoprecipitation (ChIP) analysis using either REST or IgG (control)  antibody. qRT-
PCR was performed using primers corresponding to sites present on the miR-124 
promoter elements  site # 1 (-2648)  and site #2 (-300) (non-specific)  upstream of the 
Transcriptional start site (TSS) and  miR-203 promoter elements: site # 1 (-223), site #2 
(-512) , site # 3 (-762), site # 4  (-1223) upstream of the TSS , the potential RE1 site 
and an additional random site, site #5.  REST was found to bind  to site #1 gene 
A 
B 
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chromatin of miR-124 and only at site #4 of miR-203 indicating specific REST binding 
sites.(Fig 10A & 10B) 
 
 
 
Figure 10: miR-124 and miR-203 are the transcriptional targets of REST. Predicted 
RE1 binding sites upstream of miR-124 and miR-203 TSS are represented (A &B).  
ChIP was performed in HR-GSC with anti-REST antibody or and IgG control followed 
by qPCR analysis using primers specific for the predicted RE1 sites upstream of miR-
124 or miR-203. Student’s t test was performed to determine the statistical significance. 
 
 
To determine whether the single REST binding site present in the miR-124 or  miR-203 
gene chromatin directs REST-dependent expression, we sub cloned the site in front of 
a luciferase reporter gene.  For comparison, we also used no site or a mutated version 
of the site.  We then transfected the plasmids in HR-GSC1/2/shNT and HR-
GSC1/2/shRest cells and determined luciferase activity in the resulting cells.  Results 
A 
B 
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shown in  Fig. 11 indicated that when no site was present or when the site was 
mutated, luciferase activity was similar in the shNT- and sh/Rest-expressing HR-GSC 
cells.  In contrast, when the REST binding site was present, luciferase activity was 
higher in shRest-expressing cells than in shNT-expressing cells. Thus, taken together, 
these results indicated that REST directly targets miR-124 and miR-203 in GSCs. 
 
 
A 
B 
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Figure 11: REST targets miR-124 and miR-203 gene expression through specific 
sites on gene chromatin. A & B: We performed reporter gene analysis using a 
plasmid containing luciferase gene downstream of wither the specific REST binding site 
present on the miR-124 gene chromatin, a mutated version of the site or no site 
transfected into HR-GSC1sh  NT,HR-GSC 1 shREST (A), HR-GSC2 shNT,HR-GSC2 
shREST (B) cells and measured the luciferase activity. Similar experiment was 
performed with the miR-203 gene chromatin binding region (C &D).  Luciferase activity 
remained unaltered when an empty vector was expressed in either shNT or shREST 
expressing cells, it increased in shREST when compared to shNT when the plasmid 
contained the REST binding site. The increase of the activity is further reversed when 
the plasmid contained the mutated binding site. 
 
Both the microRNAs miR-124 and miR-203 are identified as potential targets of REST 
that might play a role in GSC tumorigenesis. Both these microRNAs are identified as 
tumor suppressor microRNAs in other cancers. Studies have shown that both these 
C 
D 
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microRNAs are highly repressed in GBM tumors when compared to normal brain.  
Studies have also shown that miR-124 plays a important role in migration and invasion 
in glioblastoma. Loss of miR-124 leads to stem cell like traits and more invasiveness of 
these cells. miR-124 is a known target of REST in NSCs and ES cells. Studies have 
shown that miR-124 targets cyclin dependent kinase 6(CDK6) and there by regulates 
the cell cycle. miR-203 is found to be highly repressed in hepatocellular carcinomas 
and hematological malignancies. Ectopic expression of these microRNAs miR-124 and 
203 in hepatocellular carcinomas resulted in inhibition of cell proliferation. 
The microRNA miR-124 is already a known target of REST in NSCs and ES cells but 
its role in GSCs is not known. MiR-203 is a novel target of REST identified in our 
screen. So we decided to investigate independently on the two axes REST-miR-124 
and REST-203 have any role on GSC tumorigenesis.  
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Summary 
Our data suggest that upon REST knock down there is an up regulation in the 
expression levels of miR-124 and miR-203 in GSCs.  Also, upon REST overexpression 
there is a down regulation of both these microRNAs. We have also shown that REST 
binds to the RE-1 sites located at 2.6kb and 1.2kb upstream of the TSS for miR-124 
and miR-203 respectively. Our findings from luciferase assay further confirmed that 
there is an increase in the luciferase activity in the presence of REST binding site in 
shREST cells when compared to its controls (shNT). In contrast, when no binding site 
was present or when it was mutated there was no difference in the luciferase activity in 
REST knock down cells (HR-GSC shRest) and its controls (HR-GSC shNT).  These 
results indicate that REST directly targets miR-124 and miR-203 in GSCs. 
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Chapter 5: REST-miR-124 axis regulates oncogenic properties of GSCs in vitro 
and in vivo 
 
Rationale 
In the previous section, we identified miR-124 as a potential target of REST. We 
observed a reciprocal relationship in the expression of the microRNA miR-124 and 
REST. We further determined that REST binds to the RE 1 sites located at 2.6kb 
upstream of the TSS of miR-124 gene chromatin. This was further confirmed by 
luciferase assays. The microRNA, miR-124 mature sequences are highly conserved 
and are the most abundant miRNA in adult and embryonic brain. Based on binding and 
expression studies, miR-124 was identified as one of the earliest miRs to be a direct 
target of REST. Studies have shown that miR-124 is a part of REST regulatory network 
in neural and non-neural cells where REST represses miR-124 expression, thereby 
prevents neurogenesis and allows expression of non –neural genes. Studies have 
shown that miR-124 is up regulated during differentiation of NSCs. miR-124 is up 
regulated during neuronal differentiation and promotes cell cycle exit by inhibiting cyclin 
D, a cell cycle regulator. A miR microarray study by Sibler et al and a 
immunohistochemical study by Fowler has shown that miR-124 is down regulated in 
gliomas relative to the normal brain (82, 83). Furthermore, down regulation of miR-124 
correlates with poor survival in colorectal cancers. 
In this section we investigated if the REST-miR-124 regulatory axis regulates 
oncogenic properties of GSCs both in vitro and in vivo. We studied this hypothesis by 
generating cell lines (2 independent cell lines) with loss and gain-of-function 
(LOF/GOF) of miR-124 gain by lentiviral transductions. Expression levels of miR-124 
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were confirmed by taqman assays and tumorigenic assays were performed both in vitro 
and in vivo. We performed proliferation, apoptosis and invasion assays in vitro on LOF 
and GOF miR-124 cells. After characterizing the cells in vitro we implanted the cells 
into the brains of nude mice and performed Kaplan Meir survival analyses. Further, we 
performed proliferation, apoptosis and invasion assays on tumor sections. 
Confirmation of over expression or knock down of miR-124 expression 
Two independent HR-GSCs and their respective REST knock down cells were 
obtained and cultured. A schematic representation of experimental design is shown in 
figure 12. 
 
Figure 12:  Schematic representation of experimental design. High REST GSCs 
have higher expression levels of REST and low expression of miR-124.  We used this 
line to overexpress the miRs using lentiviruses. The REST knock down lines have 
lower expression of REST and are high levels of miR-124. Lentiviral knock downs of 
the miR-124 were performed in REST knock down lines. 
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Gain of Function: HR-GSCs have higher expression levels of REST and lower 
expression of miR-124. We transduced two HR-GSC with lentiviruses containing either 
the control vector (V) or pre-miR-124. The generated stable lines (HR-GSC1.shNT/V 
and HR-GSC1.shNT/ pre-miR-124; HR-GSC2.shNT/V and HR-GSC2.shNT/ pre-miR-
124) were selected in puromycin and the overexpression of miR-124 was confirmed by 
taqman assays. 
Loss of Function: Rest knock down cells have lower expression of REST and higher 
expression of miR-124. We transduced two REST  knock down lines (HR-GSC 
shREST) with lentiviruses containing either the control vector (V) or shmiR-124. The 
generated double knock down (shREST and shmiR-124) stable lines (HR-
GSC1.shREST/V and HR-GSC1.shREST/ shmiR-124; HR-GSC2.shNT/V and HR-
GSC2.shNT/ pre-miR-124) are selected in puromycin and the knock down of miR-124 
was confirmed by qRT-PCR. 
We observed that upon gain or loss of function of miR-124 there is an increase and 
decrease in the expression of miR-124 respectively. 
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REST-miR-124 axis regulates cell proliferation, apoptosis and invasion in GSCs 
in vitro 
To understand the mechanism by which REST-miR-124 axis regulates the oncogenic 
properties of GSCs we used the established LOF and GOF miR-124 cells and 
performed tumorigenisis assays. 
We performed a BrdU proliferation assay on the miR-124 GOF and LOF cells to 
determine the proliferative capacity of these cells. We observed that upon over 
expression of miR-124 (GOF) in two independent cells there is decrease in the cell 
proliferation when compared to its controls as shown in fig (13 A) .Upon knock down of 
miR-124 there is an increase in the percentage of BrdU incorporated cells indicating 
these cells are dividing at a higher rate when compared to its controls Fig (13 B) 
We also performed apoptosis assay, to determine the DNA fragmentation that results 
from apoptosis. We observed that upon overexpression of miR-124 there is an increase 
in the percentage of apoptotic cells when compared to its control.  Similarly upon 
knocking down of miR-124 we observed that there is a decrease in the apoptosis (Fig 
13 C & D) 
To determine the role of miR-124 in invasion, we subjected the GOF of   miR-124 cells 
for invasion assay. Upon over expression of miR-124 we observed that there is a 
decrease in the percentage of invading cells when compared to its controls.  Next we 
wanted to know if REST-miR-124 axis has any role in regulating invasion of GSCs. We 
knock down miR-124 in REST knock down cells (shREST/shmiR-124) and performed 
the invasion assay. We observed that there is an increase in the invasive potential of 
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these double knock down cells (shREST/shmiR-124) when compared to its controls 
(shREST/shmiRNT). (Fig 13 E & F) 
 
 
56 
 
 
Figure 13: REST-miR-124 axis regulates cell proliferation, apoptosis and invasion 
in GSCs in vitro. A & B: We performed a BrdU Proliferation assay on GOF and LOF 
of miR-124 cells. We observed that upon over expression of miR-124 there is a 
decrease in the percentage of proliferating cells.   C & D:  Apoptotic assay was 
performed on the LOF and GOF miR-124 cells. We observed that upon overexpression 
of miR-124 there is an increase in the apoptotic cells. E &F: We performed an invasion 
assay. Upon knocking down of miR-124 there is an increase in the percentage of 
invading cells. 
                     
We have observed that over expression of miR-124 in the GSCs resulted in decreased 
cell proliferation, increased apoptosis and decreased invasion. Upon knocking down of 
miR-124 in the REST knock down cells lead to increased cell proliferation and invasion 
and decreased apoptosis. From this we can conclude that REST-miR-124 axis 
regulates the oncogenic properties of GSCs. 
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MiR-124 regulates survival of mice harboring GSC-derived brain tumors 
REST-miR-124 axis regulates the oncogenic properties of GSCs in vitro. We wanted to 
test if miR-124 has any role in regulating the tumorigenesis and affect the survival of 
the tumor bearing mice. Two independent GOF of miR-124 (HR-GSC1.shNT/V and 
HR-GSC1.shNT/ pre-miR-124; HR-GSC2.shNT/V and HR-GSC2.shNT/ pre-miR-124) 
cell lines were generated and these are implanted into the brains of the nude mice and 
Kaplan-Meier survival analyses is performed. Over expression of miR-124 in two 
independent HR-GSC lines increased the survival of tumor bearing mice, indicating 
miR-124 has tumor suppressor functions (fig 14). 
 
Figure 14: mir-124 regulates survival of the tumor bearing mice. Both the HR-
GSCs over expressing miR-124 when implanted into the brains of nude mice increased 
the survival of tumor bearing mice. 
 
 
 
 
A B 
p<0.001 
p < 0.001 
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REST-miR-124 axis regulates survival of mice harboring GSC-derived brain 
tumors 
We observed that over expression of miR-124 increased survival of  tumor bearing 
mice. We wanted to know if REST-miR-124 axis has any role in the survival of mice.  A 
previous study has shown that REST knock down cells (shRest) when implanted into 
the brain of nude mice have a longer survival than  controls (shNT). We implanted the 
double knock down cells (shREST/shmiR-124) and its control (shREST/shmiR-NT) into 
the mice and performed the survival analysis. We observed that upon double knock 
down (shREST/shmiR-124) down there is a decrease in the survival of tumor bearing 
mice when compared to its control (fig 15). These results indicate that REST-miR-124 
axis regulates the survival of mice harboring GSC derived tumors. 
 
Figure 15: REST-mir-124 regulates survival of the tumor bearing mice. Upon 
REST knock down the mice survived for longer. Double knock down of REST and miR-
124 decreased the survival of tumor bearing mice. 
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REST-miR-124 axis regulates proliferation, apoptosis and invasion in GSC-
derived tumors in mouse brains 
We observed that REST-miR-124 axis regulates proliferation, apoptosis and invasion in 
vitro. We also found that REST-miR-124 axis regulates the survival of mice. We wanted 
to determine if REST-miR-124 axis holds true in vivo. GSCs with either GOF or LOF of 
miR-124 are implanted into the brain of nude mice. Mice were euthanized around 40 
days of time and the brains were paraffin embedded and tumorigenic assays were 
performed on the mouse brain tumor sections. To distinguish human cells from mouse 
cells, the tumor sections are stained using anti-NuMa antibody that specifically stains 
only human cells. 
 To measure the proliferative index in the tumor sections , the tumor sections are 
double labelled with NuMa and Ki67( proliferative marker). Over expression of miR-124 
led to decreased cell proliferation in the tumor sections.  In the double knock down 
tumor sections (shREST/shmiR-124) there is an increase in the proliferating cells when 
compared to its control.(fig 16) 
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Figure 16:  Involvement of REST-miR-124 in cell proliferation.  The tumor sections 
are stained with human specific NuMa antibody (Green).  Ki67 (red) a proliferative 
marker stains the proliferating cells and Dapi (blue) stains all the cells of the tissue. A. 
Over expression of miR-124 decreases the ki67 positive cells.  B. Double knock down 
of REST and miR-124 resulted in increase in cell proliferation. A quantitative 
representation of the same is shown in a bar graph. 
 
We performed TUNEL assay on the tumor sections. Upon over expression of miR-124 
we observed that there is an increase in the percentage of apoptotic cells when 
compared to controls. (Fig 17) 
A 
B 
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Figure 17: REST-miR124 axis role in apoptosis in vivo. Tumor sections are 
subjected to TUNEL labelling assay.  Upon over expression of miR-124 there is an 
increase in the number of TUNEL positive cells when compared to its controls (A). 
Knock down of 124 in REST knock down cells decrease the number of apoptotic cells 
(B). 
 
 
Tumors formed by both HR-GSCs were found to be more invasive as we observed 
tumor cells invading from the core of tumor to the pial surface of the brain. But upon 
overexpression of miR-124, we observed there is decreased tumor invasion and 
tumors formed are circumscribed (fig 18A).  We wanted to check whether REST-miR-
A 
B 
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124 axis has any role in GSC tumor invasion. Double knock down of REST and miR-
124 (shREST/shmiR-124) resulted in highly invasive tumors when compared to 
controls (fig 18B). These results indicate that REST-miR-124 axis regulates cell 
proliferation, apoptosis and invasion in GSC tumors. 
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Figure18: Decreased cell invasion caused by shRest is reversed by knockdown 
of miR-124 in mouse tumors. Upon over expression of miR-124 there is a decrease 
in the invasion which is shown by staining the human cells implanted in the mouse 
brain with NuMa. Knock down of miR-124 led to the formation of more invasive tumors. 
 
 
A 
B 
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Summary 
In this section we investigated the mechanism by  which the REST-miR-124 axis 
regulates the oncogenic properties of GSCs. We observed that upon over expression 
of miR-124 there is a decrease in the proliferation of the cells, increased apoptosis and 
decreased invasion in vitro. Implantation of the GSCs with GOF of miR-124 in the 
brains of nude mice led to increased survival of the tumor bearing mice. Knock down of 
miR-124 in REST knock down cells (double knock downs) led to decreased survival of 
the tumor bearing mice indicating miR-124, is a tumor suppressor gene. In vivo 
tumorigenic assays were performed on the brain sections, we observed increase in the 
number of proliferative (ki67 positive) cells and invading cells  and decrease in 
apoptotic cells in the mice implanted with double knock down cells (shRest/shmiR-124). 
Our finding concludes that miR-124, is a target of REST and they act as an axis that 
regulates the oncogenic properties of GSCs. 
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Chapter 6. REST-miR-203 axis regulates invasion but not proliferation or 
apoptosis of GSCs 
Rationale 
Genome wide analyses have identified two microRNAs miR-124 and miR-203 that 
might play a role in regulating GSC tumorigenesis.  In chapter 3, we established that a 
reciprocal relationship exists between REST (protein) expression and miR-124/203 
expression.  Further, REST binding to the RE1 sites upstream of TSS was confirmed 
by ChIP and luciferase assays. Additionally, In chapter 4 we have identified that REST 
regulates miR-124 and there by regulates cell proliferation, apoptosis and invasive 
potential of the GSCs both in vitro and in vivo.  In the current chapter we investigated 
the role of the REST-miR-203 axis in regulating oncogenic properties of GSCs.  miR-
203 has been identified as a skin-specific microRNA and promotes epidermal 
differentiation by inducing cell cycle exit.  Expression of miR-203 has been found to be 
dysregulated in diseases like psoriasis, rheumatoid arthritis and cancers. Studies have 
shown that miR-203 is expressed at lower levels in glioma tissue when compared to 
the normal brain. Studies have shown that miR-203 regulates cell proliferation, invasion 
and apoptosis of established glioma cell lines U251. The current study mainly focuses 
on the mechanism by which REST-miR-203 axis regulates the oncogenic properties of 
GSCs. Either LOF or GOF of miR-203 cells were generated using lentiviruses as 
described in chapter 1. After confirming the expression levels of miR-203 the cells are 
subjected to in vitro tumorigenic assays (proliferation, apoptosis and invasion). Further 
the LOF and GOF cells are implanted in the nude mice and survival of the tumor 
bearing mice is analyzed. The tumor sections were evaluated for proliferation, 
apoptosis and invasive potential. 
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REST-miR-203 axis regulates invasion, but not cell proliferation and apoptosis, in 
GSCs in vitro 
To determine the roles of miR-203 in REST-mediated tumorigenicity, we first 
determined whether its manipulation in GSCs affected cell proliferation and apoptosis 
in vitro. We first used the miR-203 gain-of-function cells (HR-GSC1.shNT/V and HR-
GSC1.shNT/ pre-miR-203 HR-GSC2.shNT/V and HR-GSC2.shNT/ pre-miR-203) and 
subjected them to bromodeoxyuridine (BrdU)-labeling assay as shown in Figure 19 .We 
observed that over expression of miR-203 in two independent GSCs did not affect the 
cell proliferation. To determine the apoptotic status of these cells, we performed an 
apoptosis assay and found that over expression of miR-203 did not alter the apoptosis 
in these cells (Figure 19). 
We then determined whether the REST-miR-203 axis impacted cell proliferation or 
apoptosis.  We found earlier REST knock down cells (shREST) cells showed 
decreased proliferation rates  and higher apoptosis when compared to the control cells 
(shNT). We wanted to determine if knock down of miR-203 in REST knock down cells 
(double knockdown shRESTshmiR-203) has any impact on cell proliferation or 
apoptosis.miR-203 had no effect on shREST mediated cell proliferation and apoptosis 
in both  the HR-GSCs in vitro  as shown in figure 19 (A-D).  
             To determine the role of miR-203 in invasion in vitro, we took the miR-203 loss- 
and gain-of-function cell lines described in the preceding paragraph and determined the 
impact of these manipulations on cellular invasion using invasion chamber assays.  
The addition of exogenous miR-203 in either HR-GSC1 or HR-GSC2 cells decreased 
invasion when compared with the control vector, indicating that miR-203 negatively 
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regulates  the invasion  as shown in figure 19 .To determine whether the REST-miR-
203 axis regulates cellular invasion, we subjected both the HR-GSC1 and HR-GSC2 
cell types to shRest/shmiR-203 double knockdown.  Results showed that the 
decreased cellular invasion caused by shRest could be reversed by the addition of 
shmiR-203 as shown in Fig 19. Thus, the REST-miR-203 axis controls cellular invasion 
in GSCs in vitro. (Fig 19 E &F) 
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Figure 19:  REST-miR-203 axis regulates invasion but not cell proliferation or 
apoptosis in GSCs. miR-203 gain-of-function cells HR-GSC1.shNT/ pre-miR-203 and 
HR-GSC2.shNT/ pre-miR-203 were subjected to in vitro BrdU-labeling assays to 
determine their cell proliferation properties (A) and TUNEL-labeling assays to 
determine their apoptotic status (B) compared with their corresponding HR-
GSC1.shNT/V and HR-GSC2.shNT/V controls.  As shown, none of the miR-203 
manipulations made a significant difference either in their cell proliferation or apoptotic 
properties in either of the two HR-GSC lines.  Previous studies indicated that the 
expression of shRest in both HR-GSC1 and HR-GSC2 cells results in decreased cell 
proliferation and increased apoptosis as compared with shNT-expressing cells (17). 
Additional loss-of-function manipulations with shmiR-203 in these cells (resulting in 
double knockdown shRest/shmiR-203) did not significantly alter either cell proliferation 
(C) or apoptosis (D).   In contrast, when the same cells were subjected to invasion 
chamber assays, gain of function of miR-203 in both HR-GSC1 and HR-GSC2 cells 
decreased invasion when compared with the control vector (E). Similarly, when double 
knockdown of shRest/shmiR-203 was performed in HR-GSC1 and HR-GSC2 cells, the 
decreased cellular invasion caused by shRest was reversed by the addition of shmiR-
203 (F). 
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MiR-203 regulates survival of mice harboring GSC-derived brain tumors 
To determine whether miR-203 is relevant in the regulation of tumorigenesis, we 
determined whether its manipulation in GSCs affected the survival of mice bearing 
brain tumors derived from the altered GSCs. We performed miR gain-of-function 
experiments, in which we took the two HR-GSC control lines transduced with shNT that 
we characterized previously.  Both lines express high REST and low miR-203.  We 
transduced both these lines with lentiviruses containing either the vector (V) control or 
premiR-203, selected cells expressing the virus-encoded drug resistance, and 
confirmed the overexpression of miR-203 by taqman assays in the stable cell lines 
(HR-GSC1.shNT/V and HR-GSC1.shNT/ pre-miR-203; HR-GSC2.shNT/V and HR-
GSC2.shNT/ pre-miR-203). We then transplanted these cells into the brains of nude 
mice using a screw-guided system we had utilized before and performed Kaplan Meier 
survival analyses. Overexpression of miR-203 in either of the independent HR-GSC 
lines increased the survival of tumor-bearing mice, indicating that miR-203 has a tumor-
suppressor function in GSCs (Fig 20).  
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Figure 20: MiR-203 regulates survival of mice harboring brain tumors derived 
from both HR-GSC1 and HR-GSC2 cells. Kaplan-Meier survival plots of mice 
harboring (A) HR- HR-GSC1.shNT/V and HR-GSC1.shNT/pre-miR-203 and (B) HR-
GSC2.shNT/V and HR-GSC2.shNT/ pre-miR-203 cells show that overexpression of 
miR-203 in either HR-GSC1 or HR-GSC2 cells increased the survival of tumor-bearing 
mice, indicating that miR-203 has a tumor-suppressor function in GSCs. 
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REST-miR-203 axis regulates survival of mice harboring GSC-derived brain 
tumors 
We then determined whether the tumor suppressor function of miR-203 is 
mechanistically connected to REST.  We took the two previously studied HR-GSC 
stable lines that were transduced with shRest: HR-GSC1/shRest and HR-GSC2/shRest 
(expressing low REST and high miR-203) .As described before, REST knockdown with 
shRest in these cells causes longer survival in tumor-bearing mice.  To determine 
whether miR-203 can rescue these effects of shRest in GSCs, we performed 
shRest/shmiR-203 double knockdown in these cells.  We transduced each of the GSC 
lines with lentiviruses containing shNT control, shRest, shRest/shNT, or shRest/shmiR-
203; selected cells expressing the virus-encoded drug resistance; and confirmed the 
knockdown of miR-203 by taqman assays followed by qRT-PCR analyses.  We then 
transplanted these cells into the brains of nude mice as described in the preceding 
paragraph and performed Kaplan Meier survival analyses. The mouse survival was 
longer in the shRest-expressing HR-GSC1 cells than in the shNT controls, as 
expected.  Also, as expected, expression of additional shNT in the shRest-expressing 
cells (shRest/shNT: as a control for the expression of shmiRs) did not alter survival 
significantly. However, the double knockdown of shRest/shmiR-203 attenuated the 
increase in survival caused by shRest in these cells.  The double knockdown of 
shRest/shmiR-203 caused decreased survival when compared to the control 
shRest/shNT cells.  These results indicated that the REST-miR-203 axis regulates the 
tumorigenesis of GSCs. 
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Figure 21: REST-miR-203 axis regulates survival of mice harboring tumors derived from 
both HR-GSC1 and HR-GSC2 cells. Kaplan-Meier survival plots of mice harboring (A) 
HR-GSC1.shNT, HR-GSC1.shRest, HR-GSC1.shRest/shNT and HR 
GSC1.shRest/shmiR-203 and (B) HR-GSC2.shRest, HR-GSC2.shRest/shNT and HR-
GSC2.shRest/shmiR-203.  Knockdown of REST by shRest in HR-GSC1 and HR-GSC2 
cells caused increased survival when compared with their shNT controls, as 
expected27.  Additional expression of shNT in these shRest-expressing cells did not 
significantly alter survival.  In contrast, the double-knockdown shRest/shmiR-203 cells 
reversed the increased survival caused by single shRest in both. 
 
A 
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REST-miR-203 axis regulates invasion, but not cell proliferation and apoptosis, in 
GSC-derived tumors in mouse brains 
As described above, we found the REST-miR-203 axis regulates survival in mice 
harboring GSC tumors.  To determine whether the properties of the REST-miR-203 
axis seen in in vitro assays were also present in mouse brain tumors, we took the 
GSCs with miR-203 and REST manipulations described in the preceding sections, 
transplanted them into the brains of nude mice, waited for 40 days, euthanized all the 
mice, and examined their brain sections using immunofluorescence analysis.  To 
differentiate the human GSC cells from the mouse brain cells, we stained the tumor 
sections with anti-NuMA antibody that selectively stains human cells.  Double labeling 
of NuMA and the proliferation marker Ki67 showed that overexpression of miR-203 in 
the HR-GSC tumors or knockdown of miR-203 in the HR-GSC/shRest tumors did not 
significantly alter tumor cell proliferation. (Fig 22)   
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Figure 22: REST-miR-203 axis does not regulate proliferation in GSC –derived tumors in 
mouse brain. HR-GSC1 and HR-GSC2 cells with various REST and miR-203 manipulations 
described were transplanted into mouse brains. All mice were euthanized at day 40, and 
mouse brain sections were labeled with antibodies against NuMA (to detect human cells 
present among the mouse brain cells) and Ki67 (to detect cell proliferation).Brain sections were 
then examined using immunofluorescence analysis. Double labeling of brain sections with 
NuMA and Ki67 showed that overexpression of miR-203 in either of the HR-GSC tumors (A & 
B) or double knockdown of miR-203 in either the HR-GSC1/shRest or HR-GSC2/shRest 
tumors (C & D) did not significantly alter tumor cell proliferation. 
 
         TUNEL assays also showed that neither the overexpression of miR-203 in the 
two HR-GSC tumors nor the knockdown of miR-203 in the two HR-GSC/shRest tumors 
significantly affected apoptosis. (Fig 23) 
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Figure 23:  REST-miR-203 axis does not regulate apoptosis in GSC –derived tumors in 
mouse brains. TUNEL assay was performed on the mice brain sections. Either over 
expression of miR-203 in the two HR-GSC tumors (A & B) or knockdown of miR-203  in 
the HR-GSC/shREST tumors( C & D) did not show any significant alteration in 
apoptosis. 
            In contrast, HR-GSC1 and HR-GSC2 tumors, in which the cells were found to 
show a very high degree of migration causing cell invasion from the core of the tumor 
to the pial surface, were suppressed by overexpression of miR-203, which resulted in 
decreased cellular migration and distinct circumscribed tumors as shown in figure 24. 
The role of the REST-miR-203 axis in blocking tumor invasiveness was further 
illustrated when the decreased tumor invasion caused by knockdown of REST was 
reversed by the additional knockdown of miR-203, which resulted in a highly invasive 
phenotype in both HR-GSC1 and HR-GSC2 tumors as shown in figure. Thus, these 
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results indicated that the REST-miR-203 axis regulates invasion but not cell 
proliferation or apoptosis in GSC tumors. (Fig 24)  
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Figure 24: REST-miR-203 axis regulates the invasion in GSC-derived tumors in mouse 
brains. Overexpression of miR-203 in either of the HR-GSC tumors (A & B)) resulted in the 
blockade of invasion and the formation of circumscribed tumors.  Similarly, the decreased 
invasion seen in either of the HR-GSC tumors expressing shRest was reversed in 
shRest/shmiR-203 double-knockdown tumors (C & D).  
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Chapter 7:  Discussion 
Glioblastoma is the most common malignant adult brain tumor with an average life 
expectancy of 9-12 months (4, 22). Despite decades of basic science and clinical 
research, there is no widely used prognostic criterion for GBM patients. The 
mechanisms that initiate different tumors still remains unknown, however several 
evidences point towards role of impaired stem cell development in tumor initiation. 
GBM tumors are believed to be caused by self-renewing, glioblastoma-derived stem-
like cells (GSCs). These GSCs are resistant to chemo- and radiation therapies, and are 
believed to be responsible for tumor recurrence (1, 27, 84, 85). REST, a transcriptional 
repressor of neuronal differentiation and a known regulator of self-renewal in neural 
stem cells, has been recently identified in our laboratory and others to regulate 
tumorigenesis in GSCs. However, understanding the mechanism by which REST 
regulates oncogenic properties of GSCs is critical to developing therapeutic 
approaches. Here we report the potential mechanisms by which REST regulates 
oncogenic properties of GSCs. 
Recent evidences suggest that microRNA can be therapeutic targets for various 
cancers(63). To understand the candidate miRNAs regulated by REST we altered 
REST levels in GSCs and performed microRNA microarray. Our miRNA profiling 
identified two tumor suppressor miRNAs miR-124 and miR-203.  Studies have shown 
that both these microRNAs are expressed at lower levels in the glioma tumors when 
compared to the surrounding normal tissue. We also observed a negative correlation 
between the expression levels of REST and both these microRNAs in the cancer 
genome atlas (TCGA) datasets of GBM patients. Our results indicated that upon REST 
knock down both the microRNAs are up regulated and vice versa. REST binding to the 
81 
 
gene chromatin of miR-124/203 was confirmed by chromatin immunoprecipitation 
(ChIP) and luciferase assays.  In the current study role of REST and miR-124 an/miR-
203 axis was studied independently.  
Here, we show that REST-miR-124 axis regulates the cell proliferation, apoptosis and 
invasion in HR-GSC tumors. Over expression of miR-124 led to increased survival in 
tumor bearing mice and the tumors formed are more circumscribed.  We are the first 
ones to show that REST-miR-124 axis regulates the oncogenic properties in GSCs 
derived from the patient tumors. Studies have shown that miR-124 is the most 
abundant microRNA in adult and embryonic central nervous system (CNS)(42, 70, 82). 
Studies have also shown that down regulation of miR-124 is correlated with poor 
survival in GBM patients (67, 86). Previous studies have shown that overexpression of 
miR-124, induced differentiation in neural stem cells, mouse ES cells and mouse 
embryonal carcinoma cells. miR-124 also promoted cell cycle arrest in established 
GBM cells that are deprived of growth factors. Growth factor signaling (EGF, FGF, and 
PDGF) and epigenetic modification of the transcriptional regulatory sequences of the 
genes that encode miR-124 are the two possible mechanisms that it is suppressed in 
GBM tumors(70, 82). Previous studies indicated that the ability of miR-124 to induce 
differentiation depends on the cell type, developmental timing and other factors.  
Abrogation of the growth factor signaling along with the overexpression of miR-124 
might enhance the cell cycle arrest and differentiation of cells. Studies have shown that 
miR-124 targets cell cycle regulators like CDK6 and its downstream targets like 
phosphorylated retinoblastoma (RB) (87) . Targeted delivery of miR-124 to the tumor 
cells may be therapeutically valuable for GBM disease treatment.  Targeted in vivo 
delivery faces many challenges including the limited stability of miRNA, rapid blood 
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clearance, off target effects and poor cellular uptake. Stable and chemically modified 
nucleotides ( locked nucleic acids, 2`-O-methylation)  can be made for delivery which 
can be delivered at the site and also can be used to augment the specific binding of 
miRNA to the miRISC complex.(88).   miRNAs can also be delivered  as a precursor by 
a plasmid through  viral vectors. As both mir-124 and miR-203 are suppressed in tumor 
tissue when compared to the surrounding brain tissue we need to overexpress both 
these microRNAs. Lower expression levels of the microRNAs should be supplemented 
with oligonucleotide mimics containing the same sequence as endogenous miRNA, 
known as microRNA mimics. These mimics should have an ability to enter the RISC 
complex and affect miRNA target mRNAs. Double stranded mimics composed of 
passenger strand (complementary sequence to mature miRNA) and guide strand 
(sequence identical to mature miRNA) should be used for delivery as they have a 
higher efficiency when compared to single stranded RNA. Synthetic conjugates such as 
cholesterol can be used for the delivery of mimics (89). Currently, there are several lipid 
–based delivery systems available for targeted delivery such as polycationic liposome-
hyaluronic acid (LPH) nanoparticles. In addition to synthetic polymer materials, 
naturally occurring polymers such as chitosan, protamine and atellocollagen and 
peptides derived from protein translocation domains can be used for delivery. The 
application of natural compounds is limited by immunogenicity. Atellocollagen exhibits 
least immunogenic response when compared to other natural polymers. Studies have 
shown that miR-34a/atellocollagen complex when delivered intratumorally in lung 
cancers suppressed tumor growth (90) . 
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Our results indicated that REST-miR-203 axis regulates only invasion of GSCs both in 
vitro and in vivo but not cell proliferation and apoptosis. The tumors formed by the 
knockdown of miR-203 are highly invasive when compared to their controls and the 
mice die much faster. One of the principal reasons of our failure to provide better 
therapeutic approaches for GBM patients is due to the invasive nature of these tumors. 
Previously, it was found that REST regulates invasion of HR-GSCs (17, 18). However, 
the mechanism of this process was unclear.  Here, we show that a novel REST-miR-
203 axis regulates invasion in HR-GSC tumors, with REST suppressing miR-203 gene 
expression and miR-203 functioning as a tumor suppressor.  Earlier ChIP-Seq assays 
using a mouse kidney cell line had indeed found miR-203 to be a potential target of 
REST in those cells (91).  The finding that REST also represses miR-203 in HR-GSCs 
indicates that this regulatory axis likely operates in many different cell types. Recent 
observation that miR-203 expression was significantly lower in a large number of high-
grade GBM tumor tissues than in low-grade glioma tissues or normal brain tissues (92, 
93), would support miR-203’s role as a tumor suppressor in GBM.  In addition, miR-203 
is also known to act as a tumor suppressor in other cancers (94) . 
Interestingly, the publications on GBM cited above also indicated that miR-203 
positively regulated invasion as well as cell proliferation in some glioma cell lines (92, 
93) . However, our studies indicate that the REST-miR-203 axis specifically regulates 
invasion but not cell proliferation or apoptosis in HR-GSCs.  It is unclear whether this 
difference in activity is due to the use of GSCs derived from primary GBM tumors in the 
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current study rather than the glioma lines used in the other studies, as cell culture 
conditions that can affect various signaling pathways (41), or a special property of the 
HR class of GSCs. 
 
Recent studies have discovered a six-miR gene signature, which includes miR-203, in 
the serum of colorectal cancer patients that can be used as a biomarker and prognostic 
indicator (95).  While two of the miR levels were elevated in colorectal cancer patient 
serums, levels of the other four, including miR-203, were lowered.  Although lowered 
miR-203 levels were also seen in the HR-GSCs in our study, it is unknown whether 
such a miR signature exists in GBM. This needs to be addressed in future studies. Our 
study does suggest, however, that because GBM patients can now potentially be 
stratified based on the REST gene signature (28), the REST-miR-203 mechanism 
could potentially be manipulated in therapeutic approaches to block GBM invasion. 
The downstream effector molecules of the REST-miR-124/miR-203 axis are still 
unknown. There are many known targets of miR-124/miR-203 but whether any of them 
are relevant in the context of HR-GSCs is unclear. To identify relevant targets, we 
performed a genome-wide mRNA expression analysis of HR-GSC1 and HR-GSC2 
cells expressing either shNT or shREST (Stable lines). Using prediction programs we 
predicted the target genes of for microRNAs. We first filtered the genes whose 
expression was down regulated when REST was knocked down  with a fold change of 
2 or more and selected only those genes that contained potential miR-124 or miR-203 
binding site(s) in their 3’ untranslated region. Sorting for the potential targets that were 
common to both HR-GSC lines resulted in a short list of 25 and 18 genes for REST-
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miR-124 and REST-miR-203 respectively. Ingenuity pathway analysis (IPA) of the 
potential target genes of the REST-miR-124 indicated that these genes are involved in 
metabolism of amino acids, lipids and nucleic acids. Similarly, upon analysis of the 
REST-miR-203 axis target genes, the top gene ontology was found to be involved in 
cellular movement. A network map of these genes obtained by performing an Ingenuity 
Pathway Analysis indicates a large network composed of two major hubs: one 
composed of genes involved in inflammation, angiogenesis, cell growth and apoptosis; 
the other composed of genes involved in ubiquitin and GTP binding proteins.  A 
canonical pathway analysis of the 18 genes indicated that they are involved in various 
signaling, such as axonal signaling, ERK5 and p53 signaling, growth hormone signaling 
and melanocyte development. Efforts are under way in our laboratory to validate the 
actual targets of the REST-miR-124/203 axis using mouse orthotopic tumor models. 
Conclusion/Summary:  The REST-miR-124 axis regulates cell proliferation, apoptosis 
and invasion of the GSCs both invitro and in vivo. The REST-miR-203 axis specifically 
regulates the invasion potential of glioblastoma stem cells but not cell proliferation or 
apoptosis both in vitro and in vivo. Since invasion is a major hallmark of high REST 
GSC tumors and the REST-miR-203 axis could be potentially targeted to block the 
invasion. 
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